INTRODUCTION AND OBJECTIVES: Nonrising prostatespecific antigen (PSA) at radiographic progression may occur in patients with metastatic castration-resistant prostate cancer (CRPC) treated with enzalutamide. In the primary analysis of PROSPER, enzalutamide provided a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) in patients with nonmetastatic (nm) CRPC. Here we report results in patients with or without PSA progression, defined according to PCWG2, at the time of metastasis or death.
METHODS: Eligible patients with nmCRPC on bone and computed tomography scan, PSA doubling time 10 months, and PSA ! 2 ng/mL at screening continued androgen deprivation therapy and were randomized 2:1 to enzalutamide 160 mg or placebo. The primary endpoint was MFS.
RESULTS: 1,401 patients were enrolled, with a median age of 74 years (range, 50-95 years) . In all patients, enzalutamide reduced the risk of metastasis or death by 71% (hazard ratio [HR] , 0.29; 95% confidence interval [CI], 0.24-0.35; P < .0001). Overall, 869 patients (62%) did not have PSA progression at the data cutoff date of June 28, 2017 (n/N [ 725/933 [78%] in the enzalutamide group; n/N [ 144/468 [31%] in the placebo group). Enzalutamide significantly reduced the risk of metastasis or death regardless of whether patients had PSA progression (HR with PSA progression, 0.57; 95% CI, 0.45-0.73; HR without PSA progression, 0.19; 95% CI, 0.13-0.29) (Table) .
CONCLUSIONS: In patients with nmCRPC and rapidly rising PSA, enzalutamide treatment resulted in a clinically meaningful and statistically significant reduction in the risk of developing metastases or death regardless of whether patients had PSA progression. The treatment effect was even greater in patients who did not have PSA progression. This finding requires further evaluation.
Clinical trial identification: NCT02003924 Prostate cancer is the most common cancer and the second-leading cause of cancer death among males in the United States. Two second-generation antiandrogens, enzalutamide and apalutamide, were recently approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The potential clinical benefit can be represented by the number of patients needed to treat (NNT) to achieve one additional clinical outcome and the potential risk as the number needed to harm (NNH), or the NNT to observe one additional adverse event (AE). This study aimed to quantify the potential clinical benefit and risk for patients with nmCRPC in terms of the NNT and NNH with enzalutamide and apalutamide plus androgen deprivation therapy (ADT) versus ADT only.
METHODS: Clinical event rates from survival curves and grade 3/4 AE rates for enzalutamide and apalutamide were obtained from the PROSPER (NCT02003924) and SPARTAN (NCT01946204) clinical trials, respectively. The trial target populations were adult patients with high-risk nmCRPC, defined as a prostate-specific antigen (PSA) doubling time of !10 months. NNT and NNH were calculated as the inverse of the absolute difference between the event rates of enzalutamide or apalutamide versus ADT. Analyses considered four clinical outcomes at 12, 24, and 36 months: metastasis-free survival, time to PSA progression, time to first use of cytotoxic chemotherapy, and overall survival. NNH was calculated for grade 3/4 AEs.
RESULTS: Compared with ADT, for every 3.3 (95% confidence interval [CI] 3.0, 3.7), 2.8 (95% CI 2.5, 3.1), and 3.0 (95% CI 2.6, 3.7) patients treated with enzalutamide, one additional patient is free of developing metastases or death at 12, 24, and 36 months, respectively. Similarly, at the same time points, and compared with ADT, for every 3.6 (95% CI 3.2, 4.0), 2.7 (95% CI 2.4, 3.0), and 2.3 (95% C: 1.9, 2.9) patients treated with apalutamide, one additional patient is free of developing metastases or death. One additional patient avoids PSA progression for every 1.4 (95% CI 1.3, 1.4) patients treated with enzalutamide or apalutamide versus ADT over 12 months. The NNH for grade 3/4 AEs was !40 for enzalutamide and !20 for apalutamide.
CONCLUSIONS: Low NNT results and high NNH results indicate that for men with nmCRPC, treatment with new second-generation antiandrogens offers clinical benefit with corresponding low risks.
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